YYYulia D. Yukhnovskaya

Yulia D. Yukhnovskaya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yulia D. Yukhnovskaya has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical and functional profile of patients with severe eosinophilic asthma with rapid response to benralizumab therapy (super-responders): a single-center retrospective study

    by Irina V. Mayorova, Майорова Ирина Вячеславовна, Olga A. Mukhina, Мухина Ольга Алексеевна, Marina S. Lebedkina, Лебедкина Марина Сергеевна, Elena N. Bobrikova, Бобрикова Елена Николаевна, Yulia D. Yukhnovskaya, Юхновская Юлия Дмитриевна, et al.

    BACKGROUND: Benralizumab therapy in severe eosinophilic bronchial asthma demonstrates a heterogeneous clinical response. The identification of a group of patients who rapidly achieve clinical remission (super responders) and the analysis of their initial characteristics are necessary for the personalization of biological therapy. AIM: to characterize the clinical and functional profile of patients with a rapid positive response to benralizumab therapy (super-responders) within 4–6 months. METHODS: A single-center retrospective observational study was conducted. The analysis included 45 adult patients with uncontrolled severe asthma and a baseline blood eosinophil count 300 cells/μL who received benralizumab in real-world clinical practice for 4–6 months. Super-response was defined as the simultaneous achievement of four criteria after 4–6 months of benralizumab therapy: no exacerbations, discontinuation of maintenance systemic glucocorticosteroids, an Asthma Control Test score ≥20, and an increase in pre-bronchodilator forced expiratory volume in 1 second of ≥100 mL. Baseline demographic, clinical, laboratory, and functional characteristics and their changes over time were assessed. RESULTS: 8 (17.8 %) out of 45 patients met the super-response criteria. Compared with the rest of the participants, the super responders were characterized by a statistically significantly shorter duration of asthma (median 6.0 years versus 16.0 years, p = 0.019), a higher baseline control level according to Asthma Control Test (median 17.0 points versus 10.0 points, p = 0.009) and a better quality of life according to Asthma Quality of Life Questionnaire (median 143.5 points versus 113.0 points, p = 0.020). With concomitant chronic polypous rhinosinusitis in the group of super responders, the initial severity of symptoms according to Sino-Nasal Outcome Test-22 was lower (p = 0.004). There were no statistically significant intergroup differences in the baseline level of peripheral blood eosinophils, the fraction of nitric oxide in exhaled air, total immunoglobulin E, and respiratory function parameters. In the general cohort (n = 45), after 4–6 months of therapy, there was a significant improvement in asthma control (Asthma Control Test, Asthma Control Questionnaire-5), quality of life (Asthma Quality of Life Questionnaire), forced expiratory volume in 1 second, and a decrease in fraction of nitric oxide in exhaled air (in all cases, p 0.05). In one-factor logistic regression models, the initial Asthma Control Test variables demonstrated a statistically significant association with the presence of a super-response (odds ratio 1.379; 95 % confidence interval 1.082–1.758; p = 0.009), Asthma Control Questionnaire-5 (odds ratio 0.355; 95 % confidence interval 0.148–0.850; p = 0.02), Asthma Quality of Life Questionnaire (odds ratio 1.035; 95 % confidence interval 1.006–1.065; p = 0.017), while Asthma Control Test is the strongest predictor of the super-response of the three presented (area under curve 0.794; average precision 0.661; sensitivity 50.0 %; specificity 100.0 %; positive predictive value (precision) 100.0 %; negative predictive value 66.7 %). No adverse events were reported during benralizumab therapy. CONCLUSION: Patients with severe eosinophilic bronchial asthma with a super-response to benralizumab therapy were characterized by a shorter disease duration and better initial symptom control, while markers of T2 inflammation (blood eosinophils, fraction of nitric oxide in exhaled air) did not demonstrate a statistically significant association with the presence of a super-response (p 0.05). The predictors of achieving a super-response were a higher initial score on Asthma Control Test and Asthma Quality of Life Questionnaire and a lower score on Asthma Control Questionnaire-5. The data obtained may contribute to the earlier initiation of anti-IL-5Rα therapy and the prediction of the expected clinical response.

  • Recurrent angioedema with normal C1-inhibitor: genetics determine the endotype

    by Marina S. Lebedkina, Darya S. Fomina, Elena N. Bobrikova, Yulia D. Yukhnovskaya, Anna A. Roppelt, Tatyana S. Kruglova, Olga A. Mukhina, Ulyana A. Mаrkina, Ekaterina A. Nikitina, Yulia G. Alekseeva, et al.

    Hereditary angioedema with normal C1 esterase inhibitor is a rare genetic disorder characterized by periodical and unpredictable angioedema without quantitative and qualitative deficiency of C1-inhibitor. According to the modern classification, this disease can present as two different endotypes: bradykinin-mediated and endothelium dysfunction-associated. Diagnosis of this disease is complicated by the need to perform genetic screening because available laboratory tests (C1-inhibitor, its functionality, and C4 protein in blood plasma) are within normal values, functional molecular tests are not available, clinical data are limited to few cohorts and, for some genetic defects, to single clinical observations. Genetic examination of patients with recurrent angioedema expands the cohort of patients with hereditary angioedema and normal C1 esterase inhibitor. The article describes 17 patients with hereditary angioedema with normal C1 esterase inhibitor who underwent treatment at a specialized center in Moscow. The bradykinin-mediated angioedema endotype was found in 13 patients (9 with mutation in PLG, 2 with mutation in FXII, and 2 with mutation in KNG1), and endothelium dysfunction-associated angioedema was diagnosed in 4 patients with mutation in MYOF (2 asymptomatic carriers). Currently, data on the clinical presentation, diagnosis, and therapy of patients are limited to single clinical cases and small clinical case series, thus further data collection is needed. The publication contains unique data on the algorithm of diagnosis and selection of therapy in patients with angioedema and normal C1-inhibitor level.

  • Open Access

    Artificial intelligence tools for molecular analysis of sensitization profiles in patients with atopic dermatitis and bronchial asthma

    by D. S. Fomina, M. S. Lebedkina, E. A. Nikitina, A. D. Dushkin, A. A. Chernov, Yu. D. Yukhnovskaya, I. V. Evsegneeva, A. V. Karaulov, M. A. Lysenko

    Background. The variety of characteristics that should be taken into account in the clinical phenotyping of allergic diseases is currently being discussed. One of such characteristics is the individual spectrum of sensitization. An important stage in modern allergology has become the introduction of molecules / components for the detection of mediated reactions to specific class E immunoglobulins. Aim. To determine the dominant phenotypes of sensitization in patients with severe atopic dermatitis and bronchial asthma based on the results of molecular diagnostics by the ImmunoCAP Immuno Solid-phase Allergen Chip (ISAC) method using machine learning. Materials and methods. The study included 100 patients who were candidates for genetically engineered biological therapy (n = 63), severe atopic dermatitis (n = 20), or their combination (n = 17) were included. Allergodiagnosis was performed by the ImmunoCAP ISAC method. Results. Based on the results of the study, 6 phenotypes were identified. In phenotype 1, pollen molecules (Amb a1, Phl p4) and crossed reactive food molecules (Mal d1, Ara h8, Gly m4, Act d8, Pru p3) are the leading, among epidermal molecules only Fel d1 (epidermal allergen) and Asp f6 (fungal allergen) are found. For phenotype 2, the significant allergens were fungal (Asp f6), epidermal (Can f1, Can f5, Can f6, Fel d1), food (Gad c1) and cross reactive food molecules (Mal d1, Pru p1. Ara h8, Cor a1.0401). In phenotype 4, only 3 allergen groups are present: epidermal (Fel d1, Fel d2, Can f5, Can f6, Can f3), fungal (Asp f6), and cross food allergy (Jug r3, Pru p3). Phenotype 5 and 6 are dominated by epidermal molecules (Can f1 and Fel d1), true food allergies allergens (Gad c1 and Gal d1 and Gad c1, Gal d1, Gal d3, respectively). In phenotype 3, a combination of the previously labeled molecules is noted. Conclusion. Each of the identified phenotypes reveals a different set of molecules that can be used in real clinical practice to develop reduced panels, making them more accessible.


  • Open Access

    Analysis of the sensitization spectrum in patients with severe allergic diseases using the ImmunoCAP ISAC method

    by Daria S. Fomina, Marina S. Lebedkina, Ekaterina A. Nikitina, Alexander D. Dushkin, Anton A. Chernov, Yulia D. Yukhnovskaya, Mariana A. Lysenko, Alexander V. Karaulov, Юхновская Юлия Дмитриевна

    BACKGROUND: An important advance in modern allergology has been made by the introduction of allergenic molecules/components, including their detection by the ImmunoCAP ISAC method. This method is useful in patients with a complex spectrum of sensitization and severe forms of allergic diseases, where various predictors of severe course are actively searched for. AIM: To evaluate the informativeness of component resolved diagnostic by ISAC ImmunoCAP method in patients with severe bronchial asthma and severe atopic dermatitis. MATERIALS AND METHODS: A single-center retrospective study was conducted from January to August 2023. 100 patients who were candidates for biologicals for severe bronchial asthma (group 1; 63 patients), severe atopic dermatitis (group 2; 20 patients), or their combination (group 3; 17 patients) were included. Component restlved diagnostic was performed by ImmunoCAP ISAC method. RESULTS: Polysensitization and high occurrence of food and fungal allergens were more frequently detected in the groups of patients with severe atopic dermatitis. When analyzing the pollen sensitization spectrum in groups 2 and 3, Bet v 1 and PR-10 family cross-linked molecules (Mal d 1, Pru p 1, Ara h 8, Gly m 4, Cor a 1.04), as well as Ole e 9, Cyn d 1, Ph p 1 and Par j 2 were the most common. Epidermal allergens were common in all three groups. Lipocains (Can f 1, Can f 4, Can f 6, Ecu q 1, Mus m 1), kallikreins (Can f 5), and albumin (Fel d 2) dominated among them. The presence of sensitization to household allergens was detected only in group 2 and only to the molecule Der p 23. Among fungal allergens, the allergen Asp f 6 was predominant in the groups with severe atopic dermatitis, and the component Alt a 1 in patients with severe bronchial asthma. Among food allergens, one of the most common allergens was the molecule Gad c 1, Gal d 1, Gal d 2, Gal d 5 and Bos d 6. CONCLUSION: Component resolved diagnostic is an accurate assay suitable for determining the spectrum of sensitization in patients; its result can serve as a distinct biomarker for severe allergic diseases.


  • Open Access

    Disease-modifying osteoarthritis drugs (DMOADs): new trends in osteoarthritis therapy

    by O. A. Shavlovskaya, V. V. Omelyanovskiy, O. A. Gromova, A. Yu. Kochish, Yu. D. Yukhnovskaya, I. D. Romanov, I. A. Bokova

    The review examines pharmacological agents that can have potential disease-modifying osteoarthritis drugs (DMOADs) status. DMOADs prevent the progression and further structural joint damage (structure-modifying effect), leading to a decrease in symptoms severity (symptom-modifying effect), such as pain, and improvement of joint function. Approaches to potential DMOADs selection are discussed: (1) the preferred target (bone, cartilage, synovia); (2) action drug mechanism/anti-cytokine therapy (matrix metalloproteinase inhibitors, inhibitors of pro-inflammatory interleukins, etc.). The main delivery systems of drugs claiming to be of DMOADs status and possible contribution of immunological mechanisms to osteoarthritis pathogenesis are considered. Methods evaluating the effectiveness of DMOADs therapy are of great interest (cytology, microscopy, radiological research methods, blood and synovia biochemical markers). Based on research results analysis, the following substances can be considered as potential DMOADs: chondroitin sulfate, glucosamine sulfate, undenatured type II collagen, vitamin D. Each of them has symptom-modifying and structural-modifying effects.


  • Open Access

    Pharmaconutraceutical Chondroguard®TRIO – chondroprotector with immunomodulatory activity

    by O. A. Shavlovskaya, Yu. D. Yukhnovskaya, I. D. Romanov, I. A. Bokova

    Understanding the major pathological pathways and the key molecules involved in the pathogenesis of inflammatory processes in joints, particularly in osteoarthritis (OA), is crucial for drug and pharmaconutraceuticals development. OA is a degenerative joint disease that predominantly affects articular cartilage. Destruction of hyaline cartilage and restructuring of subchondral bone are accompanied by synovial inflammation in the joint, including the facet joint of the spine, manifested by pain in the joint, low back pain (LBP), and limitation of functional activity. The article discusses the relationship between immune and inflammatory mechanisms in OA of any location, including the joints of the spine. One of the mechanisms for the formation of a “vicious circle of inflammation” during the activation of discoidin receptors by endogenous type II collagen is discussed, leading to the induction of the synthesis of pro-inflammatory mediators: tumor necrosis factor α(TNFα), metalloproteinases (MMPs) 1 and 13, interleukins (IL) 1 and 6. Inflammation, in turn, leads to a decrease in the synthesis and destruction of endogenous type II collagen and, subsequently, to cartilage destruction. Cartilage fragments entering the joint space of the intercellular matrix enhance the synthesis of TNFα, IL, and MMP and exacerbate the inflammatory process. Oral ingestion of exogenous undenatured type II collagen(NK-II) helps, first, to inactivate the binding of fragments of destroyed endogenous type II collagen to discoidin receptors and to break the "vicious circle of inflammation"; secondly, through the mechanism of oral/intestinal tolerance via the lymphoid system in Peyer's patches of the small intestine, leads to the activation of immune cells (T-lymphocytes) and initiation of the immune response – the synthesis of anti-inflammatory mediators (transforming growth factor β, IL4 and IL10). The new pharmaconutraceutical Chondroguard®TRIO, which contains chondroprotectors (chondroitin sulfate and glucosamine sulfate) as well as NK-II, will make it possible to influence the key sites of the pathological process in OA.


  • Open Access

    Pre-exposure prophylaxis of new COVID-19 coronavirus infection with tixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies

    by A A Roppelt, M S Lebedkina, A A Chernov, T S Kruglova, O A Mukhina, Y D Yukhnovskaya, F A Samedova, U A Mаrkina, G V Andrenova, A V Karaulov, et al.

    Background. Primary immunodeficiencies (PIDs), now known as inborn errors of immunity, are a group of inherited diseases caused by defects in the genes that control the immune response. Patients with PIDs have risks of developing a severe course and/or death in COVID-19. Passive immunization with long-acting monoclonal antibodies (MABs) to SARS-CoV-2 should be considered as pre-exposure prophylaxis in patients with PIDs. Tixagevimab/cilgavimab is a combination of MABs that bind to the SARS-CoV-2 spike protein. Aim. To evaluate the efficacy and safety of pre-exposure prophylaxis of new SARS-CoV-2 infection in PIDs with the combination of tixagevimab/cilgavimab. Materials and methods. Forty eight patients diagnosed with PIDs were included in the study. Median follow-up after drug administration was 174 days. The total number of confirmed coronavirus infections in patients with PIDs as well as 6 months before and after administration of MAT were assessed. Results. In the analyzed cohort, the overall incidence of COVID-19 from pandemic onset to MABs administration was 75% (36/48), with 31% (11/36) of over-infected patients having had the infection more than once. The incidence of COVID-19 immediately 6 months before the introduction of tixagevimab/cilgavimab was 40%. All patients who had COVID-19 after pre-exposure prophylaxis had a mild infection. The incidence of COVID-19 6 months after tixagevimab/cilgavimab administration significantly decreased compared to the incidence 6 months before administration (7 and 40%, respectively; p0.001). Conclusion. The use of tixagevimab/cilgavimab in patients with PIDs is effective as pre-exposure prophylaxis and reduces the risk of severe COVID-19.


  • Open Access

    Applications of a muscle relaxant (tolperizone) in clinical practice

    by O. A. Shavlovskaya, I. A. Bokova, N. I. Shavlovskiy, Yu. D. Yukhnovskaya, Ю. Д. Юхновская

    Tolperizone is a central type of muscle relaxant that is widely used in clinical practice for the treatment of patients with acute and chronic nonspecific lower back pain(LBP), inflammatory and degenerative-dystrophic joint diseases, and is used in the treatment of myofascial pain syndrome (MPS).The Russian market widely used drug tolperizone, which is comparable in its clinical and anti-inflammatory activity with the original tolperizone, as well as with non-steroidal anti-inflammatory drugs (NSAIDs). Tolperizone is prescribed mainly in complex therapy, as well as as monotherapy.In some studies, based on the clinical efficacy of tolperizone (200 mg 3 times a day), it is concluded that tolperizone can be considered as a promising treatment for acute muscle spasm, without causing drowsiness. In the treatment of pain syndromes and osteoarthritis (OA) of various localization, the optimal dosage regimen of tolperizone is currently recommended: oral 150-300 mg per day for a course of 14 days, or according to a 2-stage scheme of administration, first intramuscularly 1.0 ml 2 times a day for 5 injections, then switching to oral administration of 150 mg 3 times a day; with MPS, a single local intramuscular injection of tolperizone is prescribed at the trigger point. The addition of tolperizone (150 mg/s) to the scheme of complex therapy allows to achieve an earlier clinical effect in OA of the hip and ankle joints, suppressing further progression of the disease. When included in the therapy regimen of tolperizone (150 mg/s, 14 days) OA of the ankle joint, with ultrasound examination, there is a statistically significant decrease in the signs of synovitis.

  • Open Access

    Possibilities of chronic brain ischemia manifestations correction in outpatient practice

    by O. A. Shavlovskaya, N. I. Shavlovskiy, Yu. D. Yukhnovskaya, Ю. Д. Юхновская

    Cerebrovascular diseases (CVD) are one of the main causes of mortality and permanent disability in patients. Chronic brain ischemia (CBI) is a slowly progressive dysfunction of the brain with gradually increasing defects in its functioning, which is accompanied by energy deficiency. Early use of energy correctors, one of the representatives of which is ethylmethylhydroxypyridine succinate (EMHPS), is recommended to preserve the viability of nervous tissue in patients with CBI. A number of experimental, clinical, and randomized studies have shown that medicinal preparation (MP) containing EMHPS improve brain metabolism and blood supply, improve microcirculation, and reduce platelet aggregation. The main mechanisms of action are: antioxidant and membranotropic effects, the ability to reduce glutamate excitotoxicity, modulate the functioning of receptors and membrane-bound enzymes, restore neurotransmitter balance, and increase the energy status of the cell. The liberal MP EMHPS included in the standards of medical care for patients with stroke, angina pectoris, acute myocardial infarction. The presented data from the results of numerous studies and our own observation indicate that it is possible to correct cognitive, motor, coordination, and adaptive capabilities while taking EMGPS. Used for today the scheme of appointment of EMHPS in patients with CBI: starting from 500 mg once a day intravenously (i/v) in drip for 14 days, followed by a transition to oral reception (o/r) at a dose of 250 mg 3 times a day, a course of 60 days.